-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Inspira Technologies Granted Patent By The Israeli Patent Office For Key Safety Component For The INSPIRATM ART System
Inspira Technologies Granted Patent By The Israeli Patent Office For Key Safety Component For The INSPIRATM ART System
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that the Israeli Patent Office (ILPO) granted a patent for a key safety component of the INSPIRATM ART system.
The component is to be located on the patient's neck and is designed to secure a neck cannula from moving or dislodging. Cannula movement can occur during a change of a patient's posture in bed, during physiotherapy treatment, while an awake patient is taken by the medical staff out of bed for a short walk and/or during transportation within and between hospitals.
"We believe that the grant of this patent is another validation of our innovation and supports our core mission for the INSPIRA ART system – to reduce the dependency on invasive mechanical ventilation and improve patient safety and outcomes," stated Inspira's CEO, Dagi Ben-Noon. "This patent is part of the Company's portfolio of patents that are at various phases of the filing process and which we expect to see progress to grant status."
The ILPO is a certified International Searching and Examining Authority (ISA), appointed by the World Intellectual Property Organization (WIPO), and a party to the PCT-PPH Program, an international initiative amongst 30+ national patent offices to promote work-sharing and enable accelerated patent applicant processing. The Company plans to file for patent coverage in additional countries.
Enhances Usability and Medical Value of INSPIRA ART System
The newly patented technology shall be a key component of the INSPIRA ART system, a potential new mode of acute respiratory care under development, designed to minimize the need for invasive mechanical ventilation allowing the patient to remain awake and maintain spontaneous breathing
The component will be utilized during INSPIRA ART treatment with awake patients, potentially allowing them to be mobile with reduced risk of cannula movement and subsequent bleeding. The Company believes that such improvement in patient safety and mobilization increases patient benefit and enhances the INSPIRA ART system's usability and comprehensive medical value to both patient and medical staff, which may accelerate market adoption.
Potential Use For ECMO
While the component was initially intended to be a part of the INSPIRA ART system, the Company will also explore the potential early release of the component for the Extracorporeal Membrane Oxygenation (ECMO) device market. The current ECMO market size (including devices) is estimated at $531 million per annum, with approximately 35,000 ECMO procedures performed each year.
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that the Israeli Patent Office (ILPO) granted a patent for a key safety component of the INSPIRATM ART system.
Inspira Technologies Oxy B.H.N.Ltd.具有开创性的呼吸支持技术公司(纳斯达克:IINN)(纳斯达克:IINNW)(以下简称“公司”或“Inspira Technologies”)今天宣布,以色列专利局(ILPO)为INSPIRATM ART系统的一个关键安全部件授予了一项专利。
The component is to be located on the patient's neck and is designed to secure a neck cannula from moving or dislodging. Cannula movement can occur during a change of a patient's posture in bed, during physiotherapy treatment, while an awake patient is taken by the medical staff out of bed for a short walk and/or during transportation within and between hospitals.
该组件将安装在患者的颈部,旨在确保颈部插管不会移动或移位。当病人在床上的姿势改变时,在物理治疗期间,当醒着的病人被医务人员从床上抱起来散步和/或在医院内和医院之间运送时,插管可能会发生移动。
"We believe that the grant of this patent is another validation of our innovation and supports our core mission for the INSPIRA ART system – to reduce the dependency on invasive mechanical ventilation and improve patient safety and outcomes," stated Inspira's CEO, Dagi Ben-Noon. "This patent is part of the Company's portfolio of patents that are at various phases of the filing process and which we expect to see progress to grant status."
Inspira首席执行官Dagi Ben-Noon表示:“我们认为,授予这项专利是对我们创新的又一次验证,并支持我们对INSPIRA ART系统的核心使命--减少对有创机械通气的依赖,改善患者的安全和预后。”这项专利是该公司专利组合的一部分,这些专利正处于申请过程的不同阶段,我们预计这些专利将在授予地位方面取得进展。“
The ILPO is a certified International Searching and Examining Authority (ISA), appointed by the World Intellectual Property Organization (WIPO), and a party to the PCT-PPH Program, an international initiative amongst 30+ national patent offices to promote work-sharing and enable accelerated patent applicant processing. The Company plans to file for patent coverage in additional countries.
ILPO是由世界知识产权组织(WIPO)任命的经认证的国际检索和审查机构(ISA),也是PCT-PPH计划的成员,PCT-PPH计划是30多个国家专利局之间的一项国际倡议,旨在促进工作共享和加快专利申请人的处理。该公司计划在更多国家申请专利。
Enhances Usability and Medical Value of INSPIRA ART System
增强INSPIRA ART系统的可用性和医疗价值
The newly patented technology shall be a key component of the INSPIRA ART system, a potential new mode of acute respiratory care under development, designed to minimize the need for invasive mechanical ventilation allowing the patient to remain awake and maintain spontaneous breathing
这项新的专利技术将是INSPIRA ART系统的关键组成部分,INSPIRA ART系统是一种正在开发的潜在的急性呼吸护理新模式,旨在最大限度地减少对允许患者保持清醒和自主呼吸的有创机械通气的需求
The component will be utilized during INSPIRA ART treatment with awake patients, potentially allowing them to be mobile with reduced risk of cannula movement and subsequent bleeding. The Company believes that such improvement in patient safety and mobilization increases patient benefit and enhances the INSPIRA ART system's usability and comprehensive medical value to both patient and medical staff, which may accelerate market adoption.
该组件将在对清醒患者进行INSPIRA ART治疗期间使用,有可能使他们能够活动,从而降低插管移动和随后出血的风险。该公司认为,在患者安全和动员方面的这种改进增加了患者的利益,并提高了INSPIRA ART系统的可用性和对患者和医务人员的综合医疗价值,这可能会加速市场的采用。
Potential Use For ECMO
ECMO的潜在用途
While the component was initially intended to be a part of the INSPIRA ART system, the Company will also explore the potential early release of the component for the Extracorporeal Membrane Oxygenation (ECMO) device market. The current ECMO market size (including devices) is estimated at $531 million per annum, with approximately 35,000 ECMO procedures performed each year.
虽然该组件最初的目的是作为INSPIRA ART系统的一部分,但该公司还将探索该组件在体外膜氧合(ECMO)设备市场上提前发布的可能性。目前ECMO的市场规模(包括设备)估计为每年5.31亿美元,每年大约进行35,000次ECMO手术。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧